Holland is a professor of Infectious Diseases at Duke University and a faculty member of the Duke Clinical Research Institute. His research interests include antibacterial trials, particularly for S aureus bacteremia and antibiotic-resistant pathogens, as well as the design and implementation of novel clinical trial endpoints including ordinal outcomes and quality of life measures.
Despite modest progress, Staphylococcus aureus bloodstream infections—particularly those caused by MRSA—remain a major cause of morbidity and mortality, underscoring the urgent need for novel, broad-spectrum treatments such as ceftobiprole that can address both resistant and susceptible strains.
Published: October 5th 2025 | Updated:
